The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine

项目总结/摘要 胆管癌（CCA）是一种大分子多样性的肝胆道恶性肿瘤， 占胃肠道恶性肿瘤的约3.0%，占胃肠道恶性肿瘤的10%至20%。 原发性肝癌在过去的10-20年里，CCA已经成为高度关注的焦点。 这在很大程度上是由于现在公认的越来越多的 肝内CCA在世界各国，以及与CCA的全球高 包括美国在内的一些地区的死亡率也在上升。大多数CCA患者 被诊断为晚期疾病，治疗选择有限，总体而言， 存活率很低。然而，越来越多的靶向治疗的最新进展 临床试验为改善晚期CCA的生存结果提供了一些希望 患者据我们所知，这次FASEB科学会议代表了第一次同类会议4- 一天的人全面的科学会议专门用于CCA。它汇集了 不同的高级和有才华的早期职业调查人员小组，以批判性地评估重要的 当前和不断发展的基础，转化和临床研究领域，重点是解决 继续限制在实现重大改进方面取得进展的主要挑战 在CCA预防、临床管理和患者生存结局方面。关键主题领域， 将解决的问题包括（1）肿瘤间和肿瘤内异质性的挑战，（2） 微生物组和肿瘤微环境在影响疾病进展中的作用， 治疗耐药性和免疫监视，（3）细胞起源，谱系和基因组 CCA与肝细胞癌之间的关系，（4）识别新的和更多的 用于早期CCA检测和用于监测预后的有效生物标志物特征， 治疗;（5）个性化治疗的“多组学”进展，（6）创新的临床前 CCA药物发现的建模，（7）CCA个性化的当前和新兴趋势 探索CCA治疗的新技术和新方法。额外 这个急需的会议的重要目标包括提供一个合议和协作的 支持早期职业研究者发展的环境，促进科学交流 在不同的科学和临床学科之间，导师代表性不足的研究人员 积极参与或有兴趣加入CCA研究社区，并鼓励 与国际CCA研究联盟和患者倡导组织建立联系。 最终目的是提出新的有效战略，大大减少人类的 这种致命恶性肿瘤的影响。

Project Summary/Abstract Cholangiocarcinoma (CCA) is a macro-molecularly diverse hepato-biliary tract malignancy that accounts for approximately 3.0% of gastrointestinal malignancies and between 10% to 20% of primary liver cancers. Over the past 10-20 years, CCA has become the focus of heightened interest and concern, due in large part to the now well recognized increasing incidence of intrahepatic CCA in various countries around the world, as well as with CCA’s globally high mortality rates also rising in several areas of the world, including the USA. Most CCA patients are diagnosed with advanced disease, where treatment options are limited and overall, 5-year survival rates are dismal. However recent advances in a growing number of targeted therapies and clinical trials are offering some hope for improving survival outcomes for advanced CCA patients. To our knowledge, this FASEB Scientific Conference represents the first-of-its kind 4- day in person comprehensive scientific meeting solely devoted to CCA. It brings together a diverse group of senior and talented early career investigators to critically assess important areas of current and evolving basic, translational, and clinical research focused on addressing the major challenges that continue to limit progress towards achieving significant improvements in CCA prevention, clinical management, and patient survival outcomes. Key topic areas that will be addressed include (1) the challenges of inter- and intra-tumoral heterogeneity, (2) the roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance, (3) cellular origins, lineage, and genomic relationships between CCA and hepatocellular carcinoma, (4) identification of novel and more effective biomarker signatures for early CCA detection and for monitoring prognosis and treatments; (5) advances in “multi-omics” for personalizing therapies, (6) innovative preclinical modeling for CCA drug discovery, (7) current and emerging trends in CCA personalized medicine, and (8) exploring new technologies and approaches for CCA therapies. Additional important aims of this much needed conference involve providing a collegial and collaborative environment that supports early career investigator development, promotes scientific cross-talk between different scientific and clinical disciplines, mentors underrepresented researchers actively engaged or interested in joining the CCA research community, and encourages networking with international CCA research consortiums and patient advocacy organizations. The ultimate aim is to advance new and effective strategies for greatly reducing the human impact of this highly fatal malignancy.